Liquidia Corp Files 8-K: Material Definitive Agreement

TL;DR

Liquidia Corp signed a big deal on Oct 2nd. Details TBD.

AI Summary

On October 2, 2024, Liquidia Corporation entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhibits. Specific details of the agreement and financial information are not provided in this excerpt.

Why It Matters

This filing indicates a significant new agreement for Liquidia Corporation, which could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement's nature and terms introduces uncertainty.

Key Players & Entities

• Liquidia Corporation (company) — Registrant
• October 2, 2024 (date) — Date of earliest event reported
• 919.328.4400 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $7.75 million — development milestone payments of up to $7.75 million tied to clinical development and approv
• $150 million — ntial sales milestone payments of up to $150 million tied to commercial sales outside North
• $3.5 million — , the Company agreed to pay to Pharmosa $3.5 million within 30 days following Liquidia Techn

Filing Documents

• tm2425377d1_8k.htm (8-K) — 31KB
• tm2425377d1_ex99-1.htm (EX-99.1) — 19KB
• 0001104659-24-105182.txt ( ) — 228KB
• lqda-20241002.xsd (EX-101.SCH) — 3KB
• lqda-20241002_lab.xml (EX-101.LAB) — 33KB
• lqda-20241002_pre.xml (EX-101.PRE) — 22KB
• tm2425377d1_8k_htm.xml (XML) — 4KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. First Amendment to License Agreement with Pharmosa Biopharm As previously disclosed, on June 28, 2023, Liquidia Technologies, Inc., a Delaware corporation (the "Liquidia Technologies") and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the "Company"), entered into a License Agreement (as amended, the "License Agreement") with Pharmosa Biopharm Inc., a corporation incorporated under the laws of Taiwan ("Pharmosa"), which provided for, among other things, (i) an exclusive licensing agreement between Pharmosa and the Company for the development and commercialization in North America of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and (ii) a non-exclusive license for the manufacture, development and use (but not commercialization) of such licensed product in most countries outside North America (the "Non-Exclusive License"). On October 2, 2024 (the "Effective Date"), Liquidia Technologies and Pharmosa entered into a First Amendment to the License Agreement (the "First Amendment"). The First Amendment, among other things, (i) expands Liquidia Technologies' licensed territory beyond North America to include key markets in Europe, Japan and elsewhere, (ii) adds certain potential development milestone payments of up to $7.75 million tied to clinical development and approvals in PAH and/or PH-ILD outside North America, (iii) adds certain potential sales milestone payments of up to $150 million tied to commercial sales outside North America and (iv) limits Liquidia Technologies' ability to deduct certain portions of milestone and royalty payments due to manufacturers of devices for the administration of L606 from milestone payments and royalties payable by Liquidia Technologies to Pharmosa pu

01 Other Events

Item 8.01 Other Events. On October 2, 2023, the Company issued a press release announcing the execution of the First Amendment and the Device License Agreement with Pharmosa. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated October 2, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. October 2, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer